A common mechanism links Epstein‐Barr virus infections and autoimmune diseases
Author:
- 8 December 2022
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (1) , e28363
Abstract
Epstein‐Barr virus (EBV) infection is associated with a variety of the autoimmune diseases. There is apparently no unified model for the role of EBV in autoimmune diseases. In this article, the development of autoimmune diseases is proposed as a simple two‐step process: specific autoimmune initiators may cause irreversible changes to genetic materials that increase autoimmune risks, and autoimmune promoters promote autoimmune disease formation once cells are susceptible to autoimmunity. EBV has several types of latencies including type III latency with higher proliferation potential. EBV could serve as autoimmune initiators for some autoimmune diseases. At the same time, EBV may play a promotional role in majority of the autoimmune diseases by repeated replenishment of EBV type III latency cells and inflammatory cytokine productions in persistent stage. The type III latency cells have enhanced capacity as antigen‐presenting cells that would facilitate the development of both B and T cell‐mediated autoimmunity. The repeated cytokine productions are achieved by the repeated infection of naive B‐lymphocytes and proliferation of type III latency cells that produce inflammatory cytokines. Presentation of viral or self‐antigens by EBV type III latency B lymphocytes may promote autoreactive B cell and T cell proliferation, which can be amplified by type III latency cells‐mediated cytokines productions. Different autoimmune diseases may require different kinds of pathogenic immune cells and/or specific cytokines. Frequency of the replenishment of EBV type III latency cells may determine the specific effect of the promoter functions. A specific initiator plus EBV‐mediated common promoter function may lead to development of a specific autoimmune disease and link EBV‐infection to a variety of autoimmunity.Keywords
This publication has 70 references indexed in Scilit:
- Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial CellsPLOS ONE, 2013
- EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1OncoImmunology, 2013
- Analysis of Epstein-Barr Virus-Regulated Host Gene Expression Changes through Primary B-Cell Outgrowth Reveals Delayed Kinetics of Latent Membrane Protein 1-Mediated NF-κB ActivationJournal of Virology, 2012
- Toll-Like Receptor 7 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1PLOS ONE, 2012
- Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Stimulation by means of dendritic cells followed by Epstein–Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responsesClinical and Experimental Immunology, 2007
- Epstein-Barr virus latency switch in human B-cells: a physico-chemical modelBMC Systems Biology, 2007
- The Latent Membrane Protein 1 of Epstein-Barr Virus Establishes an Antiviral State via Induction of Interferon-stimulated GenesJournal of Biological Chemistry, 2004
- Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformationSeminars in Cancer Biology, 2001
- Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expressionEuropean Journal of Immunology, 1995